Found 0 matching trials
Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depression
NAIn this proof of concept study, the investigators plan to administer iv ket...
Location
Cleveland Clinic Foundation Center for Behavioral Health
Predictive Effect of Neuroinflammatory Factors of the MECT in Treatment of Senile Depression
N/ATo compare the correlation between the clinical efficacy of MECT treatment ...
Location
Beijing Anding Hospital Affiliated to Capital Medical University
Effects of Novel Estrogens on Glucose and Lipids in Postmenopausal Prediabetic Women Veterans
PHASE2The purpose of this study is to determine the effect of a novel menopause h...
Location
Southeast Louisiana Veterans Health Care System, New Orleans, LA
Study to Evaluate the Effects of Synthetic Conjugated Estrogens, B (SCE-B) on Nocturnal Vasomotor Symptoms in Postmenopausal Women
PHASE4This is a multi-center study to evaluate the effects of SCE-B on nocturnal ...
Location
Duramed Investigational Site
Treat Clozapine ( CLZ )-Resistant Schizophrenia Comparing CLZ + Haloperidol vs. CLZ + Electroconvulsive Therapy (ECT)
NAClozapine treatment resistant schizophrenia is still prevalent.The effectiv...
Location
Department of Psychiatry.Faculty of Medicine.KhonKaen University.
Heart and Estrogen-Progestin Replacement Study (HERS)
PHASE3The purpose of the study is to determine whether hormone replacement therap...
Location
University of California San Francisco
Pharmacist for Detecting Opioid Misuse
N/AOpioid use is increasing in Western countries and is associated with harms ...
Decreasing the Use of Unmodified Electroconvulsive Therapy (ECT) in an Indian Hospital
NAIn developing countries, electroconvulsive therapy (ECT) is typically deliv...
Location
Chhatrapati Shahuji Maharaj Medical University, U.P. & G.M. & Associated Hospitals
Cortisol Level After Repeated Doses of Etomidate
NAThe aim of this study is to investigate the effect of repeated doses of eto...
Study Comparing 3 New Formulations of Premarin® 0.625 mg/MPA 2.5 mg With a Reference Formulation
PHASE1The purpose of this trial is to determine the equivalence of 3 new formulat...
Location
Multiple Locations